565 related articles for article (PubMed ID: 31547815)
21. DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy.
Sun Q; Zhang J; Zhou N; Liu X; Shen Y
PLoS One; 2015; 10(2):e0112305. PubMed ID: 25647400
[TBL] [Abstract][Full Text] [Related]
22. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA
Chiu YL; Lin WC; Shu KH; Fang YW; Chang FC; Chou YH; Wu CF; Chiang WC; Lin SL; Chen YM; Wu MS
Front Immunol; 2021; 12():638309. PubMed ID: 34177889
[TBL] [Abstract][Full Text] [Related]
23. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy.
Zhai YL; Zhu L; Shi SF; Liu LJ; Lv JC; Zhang H
Medicine (Baltimore); 2016 Mar; 95(11):e3099. PubMed ID: 26986150
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
25. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.
Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J
J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896
[TBL] [Abstract][Full Text] [Related]
26. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.
Zhao N; Hou P; Lv J; Moldoveanu Z; Li Y; Kiryluk K; Gharavi AG; Novak J; Zhang H
Kidney Int; 2012 Oct; 82(7):790-6. PubMed ID: 22673888
[TBL] [Abstract][Full Text] [Related]
27. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
[TBL] [Abstract][Full Text] [Related]
28. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.
Tang M; Zhang X; Li X; Lei L; Zhang H; Ling C; Ni J; Lv J; Liu X; Chen X
Clin Exp Nephrol; 2021 Jan; 25(1):37-43. PubMed ID: 32935202
[TBL] [Abstract][Full Text] [Related]
30. Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy.
Reily C; Rice T; Crossman DK; Rizk DV
J Autoimmun; 2022 Oct; 132():102883. PubMed ID: 35987175
[TBL] [Abstract][Full Text] [Related]
31. Serum galactose-deficient immunoglobulin A1 in recurrent immunoglobulin a nephropathy after kidney transplantation: A meta-analysis.
Gong Z; Tang J; Hu W; Song X; Liu X; Mu J; Su Y
Transpl Immunol; 2023 Aug; 79():101850. PubMed ID: 37182720
[TBL] [Abstract][Full Text] [Related]
32. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
[TBL] [Abstract][Full Text] [Related]
33. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
Wang M; Lv J; Chen P; Yu G; Shi S; Liu L; Zhou X; Xu D; Zhao M; Zhang H
Nephrol Dial Transplant; 2021 Jan; 36(2):288-294. PubMed ID: 31603230
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of Yiqi Yangying Heluo Formula in the Treatment of IgA Nephropathy by Affecting Gd-IgA1 Based on BAFF Molecular Level and T Lymphocyte Immunity.
Liang Y; Zeng Q; Wang XH; Yan L; Yu RH
Biomed Res Int; 2023; 2023():5124034. PubMed ID: 36660452
[TBL] [Abstract][Full Text] [Related]
35. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
[TBL] [Abstract][Full Text] [Related]
36. Interaction between
Wang YN; Zhou XJ; Chen P; Yu GZ; Zhang X; Hou P; Liu LJ; Shi SF; Lv JC; Zhang H
J Am Soc Nephrol; 2021 Mar; 32(3):545-552. PubMed ID: 33593824
[TBL] [Abstract][Full Text] [Related]
37. Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
Sun Q; Zhang Z; Zhang H; Liu X
PLoS One; 2016; 11(11):e0166700. PubMed ID: 27870872
[TBL] [Abstract][Full Text] [Related]
38. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
39. Galactosylation of IgA1 Is Associated with Common Variation in
Gale DP; Molyneux K; Wimbury D; Higgins P; Levine AP; Caplin B; Ferlin A; Yin P; Nelson CP; Stanescu H; Samani NJ; Kleta R; Yu X; Barratt J
J Am Soc Nephrol; 2017 Jul; 28(7):2158-2166. PubMed ID: 28209808
[TBL] [Abstract][Full Text] [Related]
40. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
Makita Y; Suzuki H; Kano T; Takahata A; Julian BA; Novak J; Suzuki Y
Kidney Int; 2020 Feb; 97(2):340-349. PubMed ID: 31748116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
